Chapter 5 deals with obesity and related traits touching upon the genetic architecture of obesity traits such as WHR, BMI and also stressing the need for in vitro experiments and experiments on model organisms to elucidate the biological mechanism of obesity.
The book moves on to the next section on gene discovery efforts for monogenic disorders of β-cell dysfunction and insulin resistance. While T2D is affected by a combination of genes and environment, monogenic forms of T2D are more genetically enriched. The advent of NGS has helped in the diagnosis of monogenic diabetes and also in the discovery of novel aetiologies. This chapter describes the application of targeted NGS for clinical diagnostic testing or screening of known genes and exome analysis for novel gene discovery. The strategy for discovery and diagnosis of gene variants in neonatal diabetes and MODY (maturity onset diabetes of the young), has been detailed. The importance of genetic testing and treatment changes due to mutations in genes with high translational potential is also emphasized.
In the next section on 'Omics' of T2D and related traits, the new field of epigenetic modifications in T2D is reviewed well. Studies from islet transcriptome and the insight gained in β-cell biology and T2D pathogenesis are also explained. How transcriptome analysis serves as a tool for disease biology understanding is well accounted for. This is followed by genomics of adipose tissue and advancement in understanding of its role in obesity and its traits.
In the next section translational aspects of genetic association signals is dealt with. The importance of continuing genetic, epigenetic and transcript data to understand the importance of gene variants discovered by GWAS has been discussed. A good account on the future directions of functional translation which will deliver to clinical medicine is also available. The book, next discuss the advancements in the study of mouse models for understanding molecular mechanisms of diabetes and obesity. The FTO gene has been identified as one of the obesity associated genes.
The last section of the book deals with clinical translation. The challenges of defining drug response in diabetes have been discussed along with the potential and future of this area of research. Whether it is possible to get the right drug at the right dose for the right person is a million dollar question. But the potential of genomic research is taking us closer to that objective. The last chapter gives an account on the translation of genetics of diabetes into the clinic. The clinical impact of genetic diagnosis is discussed, taking MODY as an example. The chapter ends with a discussion on the myriad clinical potentials of genomics, where patient stratification, prediction of risk of diabetes and its complications, therapeutic stratification and the discovery of novel therapeutic targets are possible. This book is written by experts in various domains of genomics of diabetes mellitus, so, the perspectives in each area have been brought out succinctly. The need for international collaboration comes out strongly in the book. Thorough referencing and a well connected idea is one of the major features of this volume. Clinicians interested in diabetes and researchers in the field of genetics of T2D, will benefit by reading this book. This book is motivating and leaves the reader full of new ideas. This book is recommended for clinicians and scientists working in the field of genomics of T2D. There has been a recent upsurge of interest in the human gut microbiome because of potential new treatments in the form of faecal microbial transplant (FMT) for diverse conditions ranging from inflammatory bowel disease (IBD) to recurrent Clostridium difficile infection (CDI). The impetus into this field came with the introduction of the 16S rRNA gene sequencing which by virtue of its species-specific signature sequences replaced the old culture technique of identifying the gut bacteria. Growing evidence suggests that the human microbiome may play an important role in several diseases other than IBD.
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This book gives a broad outline of the interplay between these factors and suggests future therapeutic targets for the treatment of IBD. It is divided into three sections: the initial chapters deal with the pathogenesis of IBD followed by an intermediate section dealing with the manipulation of the gut microbiome as a potential therapy for IBD. The final section deals with the future of nutritional therapy in IBD. In the chapter on epidemiology of IBD, the author brings forth the argument that the increase seen in the incidence of IBD in many areas of the world could be attributed to the improved access to healthcare and availability of improved diagnostic tools. Increased awareness of IBD among clinicians coupled with changes in cultural norms where people have a greater willingness to discuss their bowel symptoms could also be contributory factors in the "pseudo increase" in the prevalence of IBD. In line with Western literature, the author gives evidence for the role of prior enteric infections as a risk factor for the development of IBD. The biggest stumbling block to this argument would remain that the prevalence of IBD is lowest in those areas of the world where enteric infections are most prevalent such as in Asia and Africa.
In the chapter on design of clinical trials for IBD, the author makes a strong case for the cluster randomization trials as the preferred modality for future clinical trials as these are particularly useful to evaluate complex interventions such as treatment algorithms. The superiority of the Mayo Clinic score over the Truelove-Witts criteria as a measure of outcome in Ulcerative Colitis (UC) has been highlighted as it takes into account both the symptoms as well as the endoscopic findings. It has been suggested that in the future, endoscopic assessment may be the only outcome measure in UC given that there is a good relationship between endoscopic activity and severity of symptoms.
The next chapter discusses the composition of the microbiome in healthy individuals which differs from those with IBD. While a high bacterial diversity with predominance of Bacteroides and Firmicutes is seen in healthy individuals, the dysbiosis in IBD is characterized by decreased bacterial diversity and certain Clostridial subsets notably Faecalibacterium prausnitzii. F. prausnitzii is an efficient producer of short-chain fatty acids (SCFA), which have a protective effect on the mucosal barrier function. SCFA are also critical for the development of tolerance to gut commensals. The high bacterial diversity in a healthy microbiome is responsible for the resistance to colonization by C. difficile unless the balance tilts in its favour by exposure to broad-spectrum antibiotics. Infants exposed to antibiotics in early life are more prone to IBD at a later stage. Similarly the response to gluten is determined by the age at the time of exposure, as infants exposed during 1-3 years of age are most vulnerable to develop celiac disease followed by those exposed after the age of 7 months.
The role of the cross-talk between gut bacteria and the immune regulatory cells in mucosal homeostasis and immune tolerance is well discussed. Crohn's disease is proposed to be the end result of an overly aggressive TH1/TH17 cell response to a subset of luminal bacteria in the background of innate immune dysfunction. Susceptibility is determined by defects in genes involved in immune response, mucosal barrier function or enteric bacterial clearance. Correction of the dysbiosis in the gut microbiome by customized approaches, to an individual's unique bacterial profile offers an attractive target for novel approaches to treat IBD, as discussed in the second section. Metabolism of bile acids by the gut microbiota has been shown to modulate the inflammation in patients with IBD. The beneficial role of exclusive enteral nutrition with an elemental diet in patients with Crohn's disease also suggests a causative role of the gut bacteria.
Of the estimated heritability risk of IBD, as derived from twin and hereditary studies, only less than 30 per cent is explained by genetic variants discovered in genome wide association studies (GWAS). This has led to the suggestion that heritability assessments have been overestimated. Determining which IBD associated SNPs in coding regions result in functional consequences and which non-coding SNP variants regulate gene expression are important future endeavours.
Environmental factors may also alter the composition of the gut microbiome. This explains why immigrants from regions of low prevalence of IBD to Western countries progress to the same rate as the host country in the second generation. Dietary factors such as a diet rich in fruits and vegetables may have a protective effect considering that the Western diet is rich in total fats and deficient in dietary fibre.
FMT is now an established form of therapy for recurrent and difficult to treat CDI with cure rates of > 90% and a favourable safety profile. Whether the success of FMT in CDI can be repeated in case of IBD remains to be seen. The logistic, legal, social and ethical issues are well discussed in the chapter on FMT.
The last chapter of the book deals with the new targets and unmet needs in the field of IBD therapy.
The gastroenterologists have borrowed the concept of "treat to target" from rheumatologists wherein the treatment is stepped up to achieve a defined target by using objective outcome measures.
All chapters provide a brief overview of the topics without going into the finer details of basic sciences thus enabling the physician / gastroenterologist to gain an insight into the topic. All those who have an interest in the gut microbiology especially those planning to initiate research in this exciting field should read this book. Violence is ubiquitous. Its diverse forms have destructive consequences and significantly affect the lives of people, families and communities worldwide. Its negative consequences include substance addiction, depression, suicide, school dropout, unemployment and recurrent interpersonal difficulties. Violence affects the lives of millions of people with long-lasting impact. It hampers development and recovery in conflict-ridden countries exacerbating societal divisions, perpetuating poverty, spreading crime and occasionally leading to war.
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This Report jointly brought out by the World Health Organization, United Nations Development Programme and the United Nations Office on Drugs and Crime focuses on interpersonal violence. It documents the progress made by countries in implementing the recommendations of the 2002 "World report on violence and health." The Report specifically aimed to collect data on violence to inform planning and action. It assessed the status of current programmes, policy and legislative measures and examined available healthcare, social and legal services for victims. It also aimed to identify gaps in national plans.
Data for the Report were systematically collected using a four-step process: (i) detailed questionnaires were provided to key respondents across government ministries, (ii) consensus meetings were held, (iii) validation of data submitted against independent databases, and (iv) review of the final Report. The Report highlights data from 133 countries, covering 6.1 billion people and representing 88% of the world's population. It lists the national plans, deterrence strategies, prevention programmes, legal statutes, victim services, and databases. The country profiles catalogue national action plans related to different types of violence, firearm and alcohol use in addition to social and educational policies.
It recognizes that deaths and injuries are only a fraction of the burden of interpersonal violence. The Report also documents the fact that key data on violence are often lacking. It bemoans that national action plans are not always informed by evidence. It recognizes that while countries are beginning to invest in prevention, the scale of interventions do not match the burden of violence. It highlights that while violence prevention laws are widely enacted, their enforcement is often inadequate. It acknowledges that the services and support for victims vary markedly across regions and countries.
The Report argues for improved data collection, evidence-based action, comprehensive national plans and their integration with health and social service platforms. It argues for the need to strengthen the global violence prevention agenda, and mechanisms for leadership and coordination, to increase collaboration between countries, international organizations and donors and build capacity. It suggests that interpersonal violence is a universal challenge, and that no country can rest on its laurels unless it is successfully addressed.
The Report provides an overview of efforts to prevent interpersonal violence across countries. It summaries problems, perspectives and suggests recommendations to improve services and reduce violence. It lists the current state of the efforts being made towards violence prevention against which future progress can be measured.
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